MARK3 Antibody

• 产品编号：CST-9311S      品牌：CST       原厂货号：9311S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

MARK3 抗体识别内源性的MARK3总蛋白。没有观察到与其它家族成员发生交叉反应。通过合成与人源MARK3蛋白Asn500邻近氨基酸序列一致的肽段，免疫动物从而制备出多克隆抗体。通过蛋白A和多肽亲和层析纯化抗体。微管相关蛋白调节微管的稳定性和控制相关进程例如细胞极化/分化、轴突生长、细胞分裂和细胞器的运输(1)。丝氨酸/苏氨酸激酶的MARK (MAP/microtubule affinity-regulating kinases)家族(MARK1-4)被鉴定基于它们的有能力去磷酸化microtubule-associated proteins (MAPs)包括tau、MAP2和MAP4蛋白(2-6)。MARK蛋白在它们的微管结合区域里磷酸化MAPs，这就引起MAPs蛋白从微管上分离，并且增加了微管的动力(2-4)。至于tau蛋白，在阿尔茨海默病人中观察其磷酸化已经被假设有助于神经纤维缠结的形成。MARK激酶的过表达导致MAPs的过磷酸化 、形态学改变和细胞死亡(4)。肿瘤抑制激酶LKB1磷酸化MARK激酶和紧密相关的含有T-loops的AMP-kinases ，导致活性的增加(7)。MARK3激酶是MARK/EMK/Par-1家族的一个广泛表达的成员，其被鉴定作为Cdc25C-associated protein kinase (C-TAK1)，这是基于它的相关和磷酸化Cdc25C蛋白的能力(8)。MARK3激酶的底物包括Cdc25C磷酸酶、MAPK支架激酶Ras1 (KSR1)的抑制剂(9)、protein-tyrosine phosphatase H1 (PTPH1) (10)、plakophilin 2 (PKP2) (11)和histone deacetylases (HDACs) (12)。在DNA损伤下，MARK3激酶使Cdc25C蛋白serine 216位点磷酸化磷酸化，这允许14-3-3蛋白的优先结合，而14-3-3蛋白控制进入有丝分裂(8)。MARK3激酶也已经显示去磷酸化HDAC7蛋白中一个14-3-3蛋白结合位点，这影响亚细胞定位和HDAC 蛋白的抑制功能(12)。

1. Drubin, D.G. and Nelson, W.J. (1996) Cell 84, 335-44.
2. Illenberger, S. et al. (1996) J Biol Chem 271, 10834-43.
3. Drewes, G. et al. (1995) J Biol Chem 270, 7679-88.
4. Drewes, G. et al. (1997) Cell 89, 297-308.
5. Kato, T. et al. (2001) Neoplasia 3, 4-9.
6. Trinczek, B. et al. (2004) J Biol Chem 279, 5915-23.
7. Lizcano, J.M. et al. (2004) EMBO J 23, 833-43.
8. Peng, C.Y. et al. (1998) Cell Growth Differ. 9, 197-208.
9. Müller, J. et al. (2001) Mol. Cell 8, 983-993.
10. Zhang, S.H. et al. (1997) J. Biol. Chem. 272, 27281-27287.
11. Müller, J. et al. (2003) EMBO J. 22, 4431-4442.
12. Dequiedt, F. et al. (2006) Mol. Cell Biol. 26, 7086-7102.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: Monkey, Bovine, Dog

Specificity / Sensitivity

MARK3 Antibody detects endogenous levels of total MARK3 protein. No cross-reactivity is observed with other family members.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide surrounding Asn500 of human MARK3. Antibodies were purified by protein A and peptide affinity chromatography.

Background

Microtubule associated proteins regulate the stability of microtubules and control processes such as cell polarity/differentiation, neurite outgrowth, cell division and organelle trafficking (1). The MARK (MAP/microtubule affinity-regulating kinases) family (MARK1-4) of serine/threonine kinases was identified based on their ability to phosphorylate microtubule-associated proteins (MAPs) including tau, MAP2 and MAP4 (2-6). MARK proteins phosphorylate MAPs within their microtubule binding domains, causing dissociation of MAPs from microtubules and increased microtubule dynamics (2-4). In the case of tau, phosphorylation has been hypothesized to contribute to the formation of neurofibrillary tangles observed in Alzheimer's disease. Overexpression of MARK leads to hyperphosphorylation of MAPs, morphological changes and cell death (4). The tumor suppressor kinase LKB1 phosphorylates MARK and the closely related AMP-kinases within their T-loops, leading to increased activity (7).MARK3 is an ubiquitously expressed member of the MARK/EMK/Par-1 family that was identified as Cdc25C-associated protein kinase (C-TAK1) based on its association and ability to phosphorylate Cdc25C (8). MARK3 substrates include Cdc25C phosphatase, MAPK scaffold kinase suppressor of Ras1 (KSR1) (9), protein-tyrosine phosphatase H1 (PTPH1) (10), plakophilin 2 (PKP2) (11), and histone deacetylases (HDACs) (12). MARK3 phosphorylates Cdc25C on serine 216 in response to DNA damage which allows for the preferential binding of 14-3-3 proteins that control entry into mitosis (8). MARK3 has also been shown to phosphorylate HDAC7 on one of its 14-3-3 binding sites that effects both the subcellular localization and repressive function of the HDAC (12).

1. Drubin, D.G. and Nelson, W.J. (1996) Cell 84, 335-44.
2. Illenberger, S. et al. (1996) J Biol Chem 271, 10834-43.
3. Drewes, G. et al. (1995) J Biol Chem 270, 7679-88.
4. Drewes, G. et al. (1997) Cell 89, 297-308.
5. Kato, T. et al. (2001) Neoplasia 3, 4-9.
6. Trinczek, B. et al. (2004) J Biol Chem 279, 5915-23.
7. Lizcano, J.M. et al. (2004) EMBO J 23, 833-43.
8. Peng, C.Y. et al. (1998) Cell Growth Differ. 9, 197-208.
9. Müller, J. et al. (2001) Mol. Cell 8, 983-993.
10. Zhang, S.H. et al. (1997) J. Biol. Chem. 272, 27281-27287.
11. Müller, J. et al. (2003) EMBO J. 22, 4431-4442.
12. Dequiedt, F. et al. (2006) Mol. Cell Biol. 26, 7086-7102.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM 
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.  
Do not aliquot the antibody